Table 1.
Patient characteristics
| Characteristics | Patients (n = 44) |
|---|---|
| Age, years | 49.6 ± 9.68 |
| Female, n (%) | 25 (56.8) |
| Weight, kg | 65.3 ± 13.2 |
| Body mass index, kg/m2 | 24.5 ± 3.3 |
| Localization/PA subtype, n (%) | |
| Unilateral adrenal lesion/aldosterone-producing adenoma | 4 (9.1) |
| Bilateral adrenal lesion/idiopathic hyperaldosteronism | 35 (79.5) |
| Bilateral adrenal lesion/unknown | 3 (6.8) |
| Familial hyperaldosteronism | 1 (2.3) |
| Unknown | 1 (2.3) |
| SBP, mmHg | 154.0 ± 9.8 |
| DBP, mmHg | 100.0 ± 5.9 |
| eGFR, mL/min/1.73 m2 | 78.5 ± 13.8 |
| <60 mL/min/1.73 m2, n (%) | 2 (4.5) |
| Serum K+, mEq/L | 4.01 ± 0.33 |
| <3.5 mEq/L, n (%) | 3 (6.8) |
| Diabetes mellitus, n (%) | 5 (11.4) |
| LDL-C, mg/dL | 127.9 ± 27.7 |
| PAC, pg/mL | 229.8 ± 396.7 |
| PRA, ng/mL/h | 0.49 ± 0.51 |
| ARR | 829.9 ± 2036.6 |
| Urinary Na+/K+ ratio | 2.3 ± 1.5 |
| Prior antihypertensive treatmenta, n (%) | 38 (86.4) |
| MR blocker | 9 (20.5) |
| Ca2+ channel blocker | 32 (72.7) |
| α-blocker | 1 (2.3) |
| β-blocker | 2 (4.5) |
| Concomitant antihypertensive agent, n (%) | 30 (68.2) |
| Ca2+ channel blocker | 29 (65.9) |
| α-blocker | 1 (2.3) |
| K+ supplements, n (%) | 6 (13.6) |
Values are means ± standard deviations, or numbers of patients (%)
ARR aldosterone-renin ratio, LDL-C low-density lipoprotein cholesterol, MR mineralocorticoid receptor, PA primary aldosteronism, PAC plasma aldosterone concentration, PRA plasma renin activity
aIn the 4 weeks before screening